"Progress included the initiation of our Phase 2a trial for KPL-716 in prurigo nodularis as well as the continued enrollment of our pivotal Phase 3 trial for rilonacept in recurrent pericarditis and our global Phase 2 trial for mavrilimumab in giant cell arteritis. Going forward, we expect to build upon this momentum with focused investment behind our product candidates, including commercial readiness activities for rilonacept, and continued execution." Clinical-Stage Pipeline Activity Rilonacept (IL-1α and IL-1β cytokine trap) Mavrilimumab (monoclonal antibody inhibitor targeting GM-CSFRα) KPL-716 (monoclonal antibody inhibitor of signaling through OSMRβ) Preclinical Pipeline Activity Financial Results and Recent Corporate Activity Financial Guidance About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.